Loading clinical trials...

A Study of YP05002 in Healthy Participants | Clinical Trials | Clareo Health

RECRUITINGPHASE1

A Study of YP05002 in Healthy Participants

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of YP05002 in Healthy Participants

NCT07089823•Yaopharma Co., Ltd.

View on ClinicalTrials.gov

Summary

This is a phase I, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, efficacy, food effect of YP05002 Tablets in healthy participants

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.
•2. Healthy male and female participants aged 18-65 years (both inclusive).No restrictions on race.
•3. In good health as determined by the Investigator, with no clinically significant findings from medical/psychiatric history, physical examination, 12-lead ECG, vital signs measurements, clinical laboratory evaluations.

Exclusion Criteria

•1. Have evidence of any clinically significant active or chronic disease.
•2. Histories of using drug that affect drug absorption, distribution, metabolism, or excretion within 14 days or within 5-half-life prior to the first dose (whichever is longer); gastrointestinal disorders with impaired gastric emptying; or prolonged use of medications that directly modulate gastrointestinal motility.
•3. Had clinically relevant acute or chronic medical conditions or diseases that would pose a risk to participant's safety or interfere with the study assessments, as determined by the Investigator.
•4. Any malignancy (except basal cell carcinoma and squamous cell carcinoma of the skin) in the previous 5 years.
•5. Diagnosis of any type of pancreatitis.

Locations (1)

Nucleus Network Melbourne Clinic

Melbourne, Victoria, Australia

Key Dates

Start Date

August 19, 2025

Primary Completion Date

April 12, 2026

Completion Date

June 30, 2026

Last Updated

August 6, 2025

Enrollment

ESTIMATED participants

Conditions

Weight Management

Interventions

YP05002

DRUG

Placebo

OTHER

Contacts

Yalei Xie

CONTACT

+86 23 63211443 xieyl@yaopharma.com

Advancing Biopsychosocial Care Training Initiative

NCT07049861

Weight ManagementObesity Prevention+3 more

View study

RECRUITINGPHASE1/PHASE2

A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity

NCT07243171

Overweight and/or ObesityWeight Management

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 6, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of YP05002 in Healthy Participants

Inclusion Criteria

Exclusion Criteria

Advancing Biopsychosocial Care Training Initiative

A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity

How a Single Workout Affects Gut Bugs in Women With Different Fitness Levels and Body Types

A Self-management Based Survivorship Intervention for Chinese Cancer Survivors

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASC30 Injection in Participants With Obesity

A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity